N/A
Completed N=756
Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea
Glaucoma, Open-Angle · Hypertension
Source: ClinicalTrials.gov NCT01976624 ↗
Enrolled (actual)
756
Serious AEs
0.1%
Results posted
Jul 2015
Primary outcomePrimary: Number of Participants With Adverse Events and Adverse Drug Reactions — 146; 134 participants
Summary
This study is a Post-Marketing Surveillance study to evaluate the safety and efficacy of bimatoprost/timolol (Ganfort®) Ophthalmic Solution to treat open-angle glaucoma or ocular hypertension in Korea.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events and Adverse Drug Reactions |
146; 134 | — |
| SECONDARY Change From Baseline in Intraocular Pressure (IOP) |
18.23; -3.28; 18.23; -3.50 | — |
Eligibility Criteria
Inclusion Criteria
- Patients treated with Ganfort® for open-angle glaucoma or ocular hypertension in clinical practice.
Exclusion Criteria
- None.
Data sourced from ClinicalTrials.gov (NCT01976624). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.